Top

Published in:

Open Access 01-12-2024 | Biomarkers | Research

The associations between peripheral inflammatory and lipid parameters, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events

Authors: Binghan Li, Zhengsheng Gu, Weisen Wang, Bingying Du, Chenghao Wu, Bin Li, Tianren Wang, Ge Yin, Xin Gao, Jingjing Chen, Xiaoying Bi, Hailing Zhang, Xu Sun

Published in: BMC Neurology | Issue 1/2024

Abstract

Background

The global prevalence of VCI has increased steadily in recent years, but diagnostic biomarkers for VCI in patients with non-disabling ischemic cerebrovascular incidents (NICE) remain indefinite. The primary objective of this research was to investigate the relationship between peripheral serological markers, white matter damage, and cognitive function in individuals with NICE.

Methods

We collected clinical data, demographic information, and medical history from 257 patients with NICE. Using the MoCA upon admission, patients were categorized into either normal cognitive function (NCF) or VCI groups. Furthermore, they were classified as having mild white matter hyperintensity (mWMH) or severe WMH based on Fazekas scores. We then compared the levels of serological markers between the cognitive function groups and the WMH groups.

Results

Among 257 patients with NICE, 165 were male and 92 were female. Lymphocyte count (OR = 0.448, P < 0.001) and LDL-C/HDL-C (OR = 0.725, P = 0.028) were protective factors for cognitive function in patients with NICE. The sWMH group had a higher age and inflammation markers but a lower MoCA score, and lymphocyte count than the mWMH group. In the mWMH group, lymphocyte count (AUC = 0.765, P < 0.001) and LDL-C/HDL-C (AUC = 0.740, P < 0.001) had an acceptable diagnostic value for the diagnosis of VCI. In the sWMH group, no significant differences were found in serological markers between the NCF and VCI groups.

Conclusion

Lymphocyte count, LDL-C/HDL-C were independent protective factors for cognitive function in patients with NICE; they can be used as potential biological markers to distinguish VCI in patients with NICE and are applicable to subgroups of patients with mWMH.

van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003.CrossRefPubMed

Rundek T, Tolea M, Ariko T, Fagerli EA, Camargo CJ. Vascular cognitive impairment (VCI). Neurotherapeutics. 2022;19(1):68–88. https://doi.org/10.1007/s13311-021-01170-y.CrossRefPubMed

Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(25):3326–44.CrossRefPubMedPubMedCentral

Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270–6. https://doi.org/10.1038/s41591-018-0297-y.CrossRefPubMedPubMedCentral

Rajeev V, Fann DY, Dinh QN, et al. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics. 2022;12(4):1639–58. https://doi.org/10.7150/thno.68304.CrossRefPubMedPubMedCentral

Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758–66. https://doi.org/10.1016/S1474-4422(20)30231-3.CrossRefPubMedPubMedCentral

Rudilosso S, Rodríguez-Vázquez A, Urra X, Arboix A. The potential impact of Neuroimaging and Translational Research on the Clinical Management of Lacunar Stroke. Int J Mol Sci. 2022;23(3):1497. https://doi.org/10.3390/ijms23031497.CrossRefPubMedPubMedCentral

Li B, Du B, Gu Z, et al. Correlations among peripheral blood markers, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events. Front Aging Neurosci. 2022;14:1023195. https://doi.org/10.3389/fnagi.2022.1023195.CrossRefPubMedPubMedCentral

Blanchard JW, Akay LA, Davila-Velderrain J, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611(7937):769–79. https://doi.org/10.1038/s41586-022-05439-w.ADSCrossRefPubMedPubMedCentral

10.

Nunes VS, da Silva Ferreira G, Quintão ECR. Cholesterol metabolism in aging simultaneously altered in liver and nervous system. Aging. 2022;14(3):1549–61. https://doi.org/10.18632/aging.203880.CrossRefPubMedPubMedCentral

11.

Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res. 2011;50(4):357–71. https://doi.org/10.1016/j.plipres.2011.06.002.CrossRefPubMed

12.

Valenza M, Birolini G, Cattaneo E. The translational potential of cholesterol-based therapies for neurological disease. Nat Rev Neurol. 2023;19(10):583–98. https://doi.org/10.1038/s41582-023-00864-5.CrossRefPubMed

13.

Baumer Y, Mehta NN, Dey AK, Powell-Wiley TM, Boisvert WA. Cholesterol crystals and atherosclerosis. Eur Heart J. 2020;41(24):2236–9. https://doi.org/10.1093/eurheartj/ehaa505.CrossRefPubMedPubMedCentral

14.

Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–43. https://doi.org/10.1016/S0140-6736(20)32332-1.CrossRefPubMedPubMedCentral

15.

Hansen SB, Wang H. The shared role of cholesterol in neuronal and peripheral inflammation. Pharmacol Ther. 2023;249:108486. https://doi.org/10.1016/j.pharmthera.2023.108486.CrossRefPubMed

16.

Gliozzi M, Musolino V, Bosco F, et al. Cholesterol homeostasis: researching a dialogue between the brain and peripheral tissues. Pharmacol Res. 2021;163:105215. https://doi.org/10.1016/j.phrs.2020.105215.CrossRefPubMed

17.

Han X, Zhang J, Chen S, Yu W, Zhou Y, Gu X. Mapping the current trends and hotspots of vascular cognitive impairment from 2000–2021: a bibliometric analysis. CNS Neurosci Ther. 2023;29(3):771–82. https://doi.org/10.1111/cns.14026.CrossRefPubMed

18.

Perez L, Heim L, Sherzai A, Jaceldo-Siegl K, Sherzai A. Nutrition and vascular dementia. J Nutr Health Aging. 2012;16(4):319–24. https://doi.org/10.1007/s12603-012-0042-z.CrossRefPubMed

19.

Nøst TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841–8. https://doi.org/10.1007/s10654-021-00752-6.CrossRefPubMedPubMedCentral

20.

Zhu X, Kong X, Chen M, et al. Blood ethylene oxide, systemic inflammation, and serum lipid profiles: results from NHANES 2013–2016. Chemosphere. 2022;299:134336. https://doi.org/10.1016/j.chemosphere.2022.134336.CrossRefPubMed

21.

Vinciguerra L, Lanza G, Puglisi V, et al. Update on the neurobiology of vascular cognitive impairment: from lab to Clinic. Int J Mol Sci. 2020;21(8):2977. https://doi.org/10.3390/ijms21082977.CrossRefPubMedPubMedCentral

22.

Pan Y, Elm JJ, Li H, et al. Outcomes Associated with Clopidogrel-Aspirin Use in Minor Stroke or transient ischemic attack: a pooled analysis of Clopidogrel in high-risk patients with Acute Non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in New TIA and minor ischemic stroke (POINT) trials [published correction appears in JAMA Neurol. 2019;:] [published correction appears in JAMA Neurol. 2021;:null]. JAMA Neurol. 2019;76(12):1466–73. https://doi.org/10.1001/jamaneurol.2019.2531.CrossRefPubMedPubMedCentral

23.

Tsai CF, Lee WJ, Wang SJ, Shia BC, Nasreddine Z, Fuh JL. Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis. Int Psychogeriatr. 2012;24(4):651–8. https://doi.org/10.1017/S1041610211002298.CrossRefPubMed

24.

Chen KL, Xu Y, Chu AQ, et al. Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening mild cognitive impairment. J Am Geriatr Soc. 2016;64(12):e285–90. https://doi.org/10.1111/jgs.14530.CrossRefPubMed

25.

Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification Consensus Study. Alzheimers Dement. 2018;14(3):280–92. https://doi.org/10.1016/j.jalz.2017.09.007.CrossRefPubMed

26.

Badji A, Youwakim J, Cooper A, Westman E, Marseglia A. Vascular cognitive impairment - past, present, and future challenges. Ageing Res Rev. 2023;90:102042. https://doi.org/10.1016/j.arr.2023.102042.CrossRefPubMed

27.

Biesbroek JM, Biessels GJ. Diagnosing vascular cognitive impairment: current challenges and future perspectives. Int J Stroke. 2023;18(1):36–43. https://doi.org/10.1177/17474930211073387.CrossRefPubMed

28.

Ogama N, Endo H, Satake S, Niida S, Arai H, Sakurai T. Impact of regional white matter hyperintensities on specific gait function in Alzheimer’s disease and mild cognitive impairment. J Cachexia Sarcopenia Muscle. 2021;12(6):2045–55. https://doi.org/10.1002/jcsm.12807.CrossRefPubMedPubMedCentral

29.

Chen Y, Wang X, Guan L, Wang Y. Role of White Matter hyperintensities and related risk factors in vascular cognitive impairment: a review. Biomolecules. 2021;11(8):1102. https://doi.org/10.3390/biom11081102.CrossRefPubMedPubMedCentral

30.

Sigfridsson E, Marangoni M, Hardingham GE, Horsburgh K, Fowler JH. Deficiency of Nrf2 exacerbates white matter damage and microglia/macrophage levels in a mouse model of vascular cognitive impairment. J Neuroinflammation. 2020;17(1):367. Published 2020 Dec 1. https://doi.org/10.1186/s12974-020-02038-2.

31.

Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease. Mol Neurodegener. 2023;18(1):46. https://doi.org/10.1186/s13024-023-00640-5.CrossRefPubMedPubMedCentral

32.

Du B, Liang M, Zheng H, et al. Anti-mouse CX3CR1 antibody alleviates cognitive impairment, neuronal loss and myelin deficits in an animal model of Brain Ischemia. Neuroscience. 2020;438:169–81. https://doi.org/10.1016/j.neuroscience.2020.05.011.CrossRefPubMed

33.

Candelario-Jalil E, Dijkhuizen RM, Magnus T, Neuroinflammation. Stroke, blood-brain barrier dysfunction, and Imaging modalities. Stroke. 2022;53(5):1473–86. https://doi.org/10.1161/STROKEAHA.122.036946.CrossRefPubMedPubMedCentral

34.

Anita NZ, Zebarth J, Chan B, et al. Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. Brain Behav Immun. 2022;100:55–69. https://doi.org/10.1016/j.bbi.2021.11.005.CrossRefPubMed

35.

Cipollini V, Troili F, Giubilei F. Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application. Int J Mol Sci. 2019;20(11):2812. https://doi.org/10.3390/ijms20112812.CrossRefPubMedPubMedCentral

36.

Jiang L, Cai X, Yao D, et al. Association of inflammatory markers with cerebral small vessel disease in community-based population. J Neuroinflammation. 2022;19(1):106. https://doi.org/10.1186/s12974-022-02468-0.CrossRefPubMedPubMedCentral

37.

Aruldass AR, Kitzbichler MG, Morgan SE, et al. Dysconnectivity of a brain functional network was associated with blood inflammatory markers in depression. Brain Behav Immun. 2021;98:299–309. https://doi.org/10.1016/j.bbi.2021.08.226.CrossRefPubMed

38.

Hou JH, Ou YN, Xu W, et al. Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology. Alzheimers Res Ther. 2022;14(1):29. https://doi.org/10.1186/s13195-022-00968-y.CrossRefPubMedPubMedCentral

39.

Shim R, Wong CH. Ischemia, Immunosuppression and infection–tackling the predicaments of Post-stroke complications. Int J Mol Sci. 2016;17(1):64. https://doi.org/10.3390/ijms17010064.CrossRefPubMedPubMedCentral

40.

Liesz A, Hu X, Kleinschnitz C, Offner H. Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke. 2015;46(5):1422–30. https://doi.org/10.1161/STROKEAHA.114.008608.CrossRefPubMedPubMedCentral

41.

Alsbrook DL, Di Napoli M, Bhatia K, et al. Neuroinflammation in Acute ischemic and Hemorrhagic Stroke. Curr Neurol Neurosci Rep. 2023;23(8):407–31. https://doi.org/10.1007/s11910-023-01282-2.CrossRefPubMed

42.

Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-Cholesterol with Evolocumab. J Am Coll Cardiol. 2020;75(18):2283–93. https://doi.org/10.1016/j.jacc.2020.03.039.CrossRefPubMed

43.

German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023;97(6):1529–45. https://doi.org/10.1007/s00204-023-03492-6.CrossRefPubMedPubMedCentral

44.

Zhu S, Wei X, Yang X, et al. Plasma lipoprotein-associated phospholipase A2 and Superoxide dismutase are independent predicators of Cognitive Impairment in Cerebral Small Vessel Disease patients: diagnosis and Assessment. Aging Dis. 2019;10(4):834–46. https://doi.org/10.14336/AD.2019.0304.CrossRefPubMedPubMedCentral

45.

Ding D, Zhou F, Cao Y, et al. Cholesterol profiles and incident cognitive decline among older adults: the Shanghai Aging Study. Age Ageing. 2021;50(2):472–9. https://doi.org/10.1093/ageing/afaa140.CrossRefPubMed

46.

Berghoff SA, Spieth L, Saher G. Local cholesterol metabolism orchestrates remyelination. Trends Neurosci. 2022;45(4):272–83. https://doi.org/10.1016/j.tins.2022.01.001.CrossRefPubMed

47.

Han F, Luo C, Lv D, Tian L, Qu C. Risk factors affecting cognitive impairment of the Elderly aged 65 and over: a cross-sectional study. Front Aging Neurosci. 2022;14:903794. https://doi.org/10.3389/fnagi.2022.903794.CrossRefPubMedPubMedCentral

48.

An Y, Zhang X, Wang Y, et al. Longitudinal and nonlinear relations of dietary and serum cholesterol in midlife with cognitive decline: results from EMCOA study. Mol Neurodegener. 2019;14(1):51. https://doi.org/10.1186/s13024-019-0353-1.CrossRefPubMedPubMedCentral

49.

Hua R, Ma Y, Li C, Zhong B, Xie W. Low levels of low-density lipoprotein cholesterol and cognitive decline. Sci Bull (Beijing). 2021;66(16):1684–90. https://doi.org/10.1016/j.scib.2021.02.018.ADSCrossRefPubMed

50.

Tcw J, Qian L, Pipalia NH, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell. 2022;185(13):2213–2233e25. https://doi.org/10.1016/j.cell.2022.05.017.CrossRefPubMedPubMedCentral

51.

Dong Y, Ding M, Cui M, et al. Development and validation of a clinical model (DREAM-LDL) for post-stroke cognitive impairment at 6 months. Aging. 2021;13(17):21628–41. https://doi.org/10.18632/aging.203507.CrossRefPubMedPubMedCentral

52.

Olsson AG, Angelin B, Assmann G, et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med. 2017;281(6):534–53. https://doi.org/10.1111/joim.12614.CrossRefPubMed

53.

Sliz E, Shin J, Ahmad S, et al. Circulating Metabolome and White Matter hyperintensities in Women and men. Circulation. 2022;145(14):1040–52. https://doi.org/10.1161/CIRCULATIONAHA.121.056892.CrossRefPubMedPubMedCentral

54.

Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254–64. https://doi.org/10.1007/s13238-014-0131-3.CrossRefPubMedPubMedCentral

55.

Kynast J, Lampe L, Luck T, et al. White matter hyperintensities associated with small vessel disease impair social cognition beside attention and memory. J Cereb Blood Flow Metab. 2018;38(6):996–1009. https://doi.org/10.1177/0271678X17719380.CrossRefPubMed

56.

Zeng W, Chen Y, Zhu Z, et al. Severity of white matter hyperintensities: lesion patterns, cognition, and microstructural changes. J Cereb Blood Flow Metab. 2020;40(12):2454–63. https://doi.org/10.1177/0271678X19893600.CrossRefPubMed

57.

Wong SM, Jansen JFA, Zhang CE, et al. Blood-brain barrier impairment and hypoperfusion are linked in cerebral small vessel disease. Neurology. 2019;92(15):e1669–77. https://doi.org/10.1212/WNL.0000000000007263.CrossRefPubMed

Title: The associations between peripheral inflammatory and lipid parameters, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events
Authors: Binghan Li
Zhengsheng Gu
Weisen Wang
Bingying Du
Chenghao Wu
Bin Li
Tianren Wang
Ge Yin
Xin Gao
Jingjing Chen
Xiaoying Bi
Hailing Zhang
Xu Sun
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Biomarkers
Published in: BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-024-03591-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The associations between peripheral inflammatory and lipid parameters, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Anti-metabolic glutamate receptor 5 encephalitis with gangliocytoma: a case and review of the literature

Partial facial paralysis induced by sialolithiasis of the parotid gland: a case report

Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonism

Don’t be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol

The value of cardiopulmonary comorbidity in patients with acute large vessel occlusion stroke undergoing endovascular thrombectomy: a retrospective, observational cohort study

Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study